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A B S T R A C T
Pyogenic granuloma, a benign skin vascular neoplasm, may be idiopathic but it is 
often related to several exogenous stimuli. In the present case it appeared in the skin 
of the right cheek of a 35-year-old man with a history of prolonged topical application 
of a tacrolimus ointment in this skin area, for the treatment of a severe facial sebor-
rheic dermatitis resistant to any other topical therapeutic procedure. The granuloma 
was excised and the clinical diagnosis was histologically confirmed. The complete 
laboratory investigation was negative for any underlying disorder. Although several 
side-effects of topical application of tacrolimus have been referred, the appearance 
of pyogenic granuloma seems to be a very rare complication only of systemically ad-
ministered tacrolimus. We believe that this is the first report of such a side-effect as-
sociated with topical application of tacrolimus on the skin. The possible pathogenetic 
mechanisms are discussed.
I n T R o d u C T I o n 
Pyogenic granuloma (PG) is a common benign vascular neoplasm of the skin and 
mucous membranes. It is typically characterized by the occurrence of solitary and 
rarely multiple, rapidly developing, hemorrhagic and ulceration-prone, pink or purple, 
angiomatous papules or nodules. PG is conventionally thought to represent a reac-
tive lesion that usually arises in response to diverse stimuli such as minor trauma and 
chronic irritation, infections, viral oncogenes, pregnancy, microscopic arteriovenous 
anastomoses and various drugs1-3. However, several studies have shown that in most 
cases PG develops without any preceding injury or predisposing dermatosis2-4. 
Seborrheic dermatitis (SD) is a chronic relapsing cutaneous disorder, clinically 
characterized by the presence of pink or erythematous thin plaques covered by fine, 
oily, whitish or yellowish scales, typically located on the face and scalp. Its prevalence 
ranges from 3% to 10% in the general population, whereas it is higher in patients with 
AIDS, neurological disorders (e.g. Parkinson’s disease) and other chronic diseases (e.g. 
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alcoholic pancreatitis and alcoholism, myocardial infarction)5. 
Topical corticosteroids and antifungals are the most commonly 
used drugs for the treatment of SD, whereas calcineurin inhibi-
tors (tacrolimus and pimecrolimus) represent a second-line 
therapy for resistant cases.
Tacrolimus (FK506) is a macrolide, produced by Strep-
tomyces tsukubaensis, which exerts its potent immunosup-
pressive effects through inhibition of calcineurin. Tacrolimus 
binds to the intracytoplasmic protein FKBP-12 creating a new 
complex which binds to calcineurin and inhibits its phosphatase 
activity. This effect blocks the dephosphorylation and nuclear 
translocation of the transcription factor, inhibiting thereby 
the synthesis of interleukin 2 and other cytokines critical to 
T-cell activation6,8. In the last two decades systemic therapy 
with tacrolimus has played a pivotal role in the management of 
patients with solid organ and hematopoietic cell transplanta-
tion (HCT)6. Topically applied tacrolimus has been approved 
for the treatment of patients with moderate to severe atopic 
dermatitis unresponsive or intolerant to conventional regi-
mens, but it has also been used as an off-label treatment for 
various cutaneous diseases7.
We present herein the case of a 35-year-old man who 
developed PG on his face after long-term topical application 
of tacrolimus ointment for treatment of SD. 
C A S e  R e p o R T
A 35-year-old , HIV-negative and otherwise healthy Cau-
casian man presented to the Center for Dermatologic Diseases 
in Limassol, Cyprus, with a 5-week-history of a solitary, rapidly 
growing and easily bleeding exophytic cutaneous lesion on his 
right cheek, that had appeared after a long term application of 
tacrolimus (Protopic ointment 0.1%, Astellas Pharma GmbH, 
Munich, Germany). In 2006 he developed a severe facial SD 
that was resistant to all modes of topical treatment, apart from 
tacrolimus that the patient used to apply on his facial skin every 
2-3 days over a period of 12 years. 
Physical examination showed a smooth red dome-shaped 
nodule (8 mm in diameter) on the right cheek that was covered 
by a partially hemorrhagic crust (Figure 1A), indicative of PG. 
Since PG rarely resolves spontaneously and often repeatedly 
bleeds, the patient refused any other treatment options and 
the lesion was surgically excised under local anesthesia. The 
formalin-fixed and paraffin-embedded surgical specimen was 
submitted for histopathological examination. The latter con-
firmed the clinical diagnosis of PG revealing numerous capil-
laries within a loose and edematous framework of connective 
tissue surrounded by a mixed inflammatory infiltrate (Figure 
1B). The patient, a physician himself, didn’t recall any trauma 
or other chronic irritation at the site of his recently emerging 
solitary lesion. The results of routine hematological, biochemi-
cal and serological tests were either negative or within normal 
range. Finally, the patient switched to other forms of therapy.
d I S C u S S I o n
The most important side-effects of systemic tacrolimus 
include nephrotoxicity, post-transplant diabetes mellitus, neu-
rotoxicity, alopecia, hyperkalemia, hypomagnesemia, hyper-
tension, hyperlipidemia, gingival hyperplasia and hirsutism6. 
In sporadic cases, systemic tacrolimus is able to induce oral 
inflammatory fibro-vascular polypoid soft tissue masses in 
patients with HCT8, however the occurrence of histologically 
confirmed PG is extremely rare9. The most common adverse-
reactions occurring after topical application of tacrolimus, 
according to the drug’s label, are erythema, pruritus, burning 
sensation, pain and paresthesia at the site of application, acne 
and increased risk of folliculitis and herpetic infections.
The exact pathogenetic mechanisms of PG still remain 
unknown; however, there is aaccumulating evidence sug-
gesting that an imbalance between angiogenesis enhancers 
(increased expression of vascular endothelial growth factor, 
basic fibroblast growth factor and decorin) and angiogenesis 
inhibitors (reduced expression of angiostatin) may be of im-
portance in the pathogenesis of PG10,11. Interestingly, in vitro 
studies showed that tacrolimus: 1. Is capable of inducing vas-
cular inflammation, endothelial activation and production of 
inflammatory cytokines through Toll-like receptor 4 (TLR4) 
activation and reactive oxygen species (ROS) generation in 
endothelial cells12; 2. Can stimulate vascular smooth muscle 
cells proliferation through activation of TGF-β13; 3. Induces 
proliferation of endothelial cells derived from umbilical 
vein14. Moreover, a recent genetic study on vessels derived 
FIguRe 1. A. Smooth red dome-shaped nodule on the right 
cheek, covered by a partially hemorrhagic crust. B. Histological 
examination of skin lesion shows numerous capillaries within a 
loose and edematous framework of connective tissue surround-
ed by a mixed inflammatory infiltrate. (H&E X 20 original mag-
nification).
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from cutaneous PG lesions identified genes of the nitric oxide 
pathway and those related to hypoxia-induced angiogenesis 
and vascular injury, like the tyrosine-kinase receptor FTL415. 
Interestingly, Groesser et al4 found out that endothelial cells in 
the lesional but not in the perilesional skin exhibit the BRAF 
c.1799T>A mutation in sporadic and secondary PG and 
identified this mutation as a major driver in the pathogenetic 
mechanisms of both types of this vascular neoplasm. 
In view of these findings it seems possible that in our 
patient, endothelial cells -upon exposure to topical tacrolimus- 
revealed an enhanced expression of angiogenetic and proin-
flammatory molecules, that led to the development of PG. 
To the best of our knowledge the case presented here is the 
first report of PG possibly associated with long-term topical 
application of tacrolimus on the skin. Naturally, the possibil-
ity that the occurrence of PG in our patient was unrelated to 
topical tacrolimus cannot be definitely ruled out; however, it 
seems unlikely in view of the occurrence of the lesion in the 
strict area of tacrolimus application and of the absence of other 
predisposing factors. In conclusion, PG should be considered 
as a possible rare side-effect of topically applied tacrolimus. 
Phycisians must be aware of this rare adverse reaction and 
capable of diagnosing and properly managing it.
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